Latest News

(UroToday.com) Rian Dickstein, MD, from Chesapeake Urology, presented on vicineum in bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Vicineum is a recombinant fusion protein antibody linked to a variant of pseudomonas exotoxin A (ETA) which is administered intravesically for 2 hours twice weekly with induction x 6wks and maintenance weekly for 6 weeks. The phase […]

(UroToday.com) Peter Black, MD, of Vancouver Prostate Center and the University of British Columbia, presented a thorough discussion regarding bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The consensus definition which was established and used by the Food and Drug Administration (FDA) which are important for clinical trials but also translational scientists which can more accurately […]

(UroToday.com) Arjun Balar, MD, New York University Langone Health, presented a discussion regarding pembrolizumab in high-risk bacillus calmette-guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). Keynote-057 focused on BCG unresponsive disease among patients with carcinoma in situ (CIS) with/without HGTa or T1 and the other arm HGTa or any T1 without CIS.

(UroToday.com) Drs. Colin Dinney, MD Anderson Cancer Center, and Peter Black, the University of British Columbia, started the meeting with a discussion regarding the history of bladder cancer research and Bladder Cancer Advocacy  Network (BCAN). In particular, they discussed the advances in understanding the biology of the disease including recent advances regarding bacillus calmette-guerin (BCG) and […]

The aim of this review was to conduct a comprehensive analysis of the role of minimally invasive salvage modalities in radio-recurrent prostate cancer and the associated clinical outcomes and toxicity profiles.

Advanced penile cancer is associated with a poor prognosis; therefore, providing patients with realistic expectations, addressing goals of care and offering palliative therapy when appropriate is critical.

The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

The aim of the study was to clarify whether clinical and/or urodynamic parameters could be used to infer the probability of neutralizing antibody (NAb) formation as a possible cause of therapy failure (non-response, NR) in patients with neurogenic detrusor overactivity (NDO) due to acquired spinal cord injury/disease (SCI/D) treated with intradetrusor botulinum neurotoxin A (BoNT-A) […]

Lower urinary tract symptoms (LUTS) are a common urological referral, which sometimes can have a neurological basis in a patient with no formally diagnosed neurological disease ("occult neurology").

Overactive bladder is defined as "urgency, with or without urge incontinence, usually with frequency and nocturia". Electroacupuncture may be a safe and an effective alternative therapy for overactive bladder, but the evidence is limited.